Retrospective Review of Percutaneous Image-Guided Ablation of Oligometastatic Prostate Cancer: A Single-Institution Experience.

[1]  Henry Knipe,et al.  Oligometastases , 2016, Radiopaedia.org.

[2]  M. Fabrini,et al.  [18F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results , 2016, Radiation oncology.

[3]  R. Santoni,et al.  Salvage Stereotactic Body Radiotherapy for Patients With Prostate Cancer With Isolated Lymph Node Metastasis: A Single-Center Experience. , 2015, Clinical genitourinary cancer.

[4]  L. Bianchi,et al.  P076 Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer , 2014 .

[5]  N. Lumen,et al.  Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial , 2014, BMC Cancer.

[6]  Jonathan M. Morris,et al.  Feasibility and oncologic control after percutaneous image guided ablation of metastatic renal cell carcinoma. , 2014, The Journal of urology.

[7]  K. Decaestecker,et al.  Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence , 2014, Radiation oncology.

[8]  J. Lynch,et al.  Rationale for Stereotactic Body Radiation Therapy in Treating Patients with Oligometastatic Hormone-Naïve Prostate Cancer , 2013, Front. Oncol..

[9]  J. Felmlee,et al.  Magnetic resonance imaging-guided cryoablation of recurrent prostate cancer after radical prostatectomy: initial single institution experience. , 2013, Urology.

[10]  N. Lumen,et al.  Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. , 2013, Clinical genitourinary cancer.

[11]  Jonathan M. Morris,et al.  Percutaneous cryoablation of musculoskeletal oligometastatic disease for complete remission. , 2013, Journal of vascular and interventional radiology : JVIR.

[12]  Sean S. Park,et al.  Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer , 2013, Front. Oncol..

[13]  C. Nanni,et al.  Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy. , 2012, European journal of radiology.

[14]  Allen C Goodman,et al.  Percutaneous cryoablation of metastatic lesions from non-small-cell lung carcinoma: initial survival, local control, and cost observations. , 2012, Journal of vascular and interventional radiology : JVIR.

[15]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. , 2011, European urology.

[16]  F. Montorsi,et al.  [11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging. , 2010, The Journal of urology.

[17]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Maggio,et al.  Endocrine complications of androgen-deprivation therapy in men with prostate cancer. , 2006, Clinical advances in hematology & oncology : H&O.

[19]  Jorge Yao,et al.  Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. , 2006, The Lancet. Oncology.

[20]  J. Goodwin,et al.  Risk of fracture after androgen deprivation for prostate cancer. , 2005, The New England journal of medicine.

[21]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[22]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[23]  J. Nelson,et al.  The treatment of prostate cancer: an overview of current options. , 2001, Cancer practice.

[24]  J. Nelson,et al.  The Treatment of Prostate Cancer. , 2001 .

[25]  N. V. As,et al.  Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis. , 2016, European urology.

[26]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. , 2014, European urology.

[27]  Mottet Nicolas,et al.  前立腺癌に関するEAUガイドライン パートII:進行性再発性および性腺摘除抵抗性前立腺癌の治療 , 2011 .

[28]  Deepinder P. Singh,et al.  Is there a favorable subset of patients with prostate cancer who develop oligometastases? , 2004, International journal of radiation oncology, biology, physics.